Clinical trial
A Multicenter, Phase 3, Randomized, Open-label, Active-controlled, Parallel-group Trial Investigating the Safety, Tolerability, and Efficacy of TransCon hGH Administered Once a Week Versus Standard Daily hGH Replacement Therapy Over 52 Weeks in Prepubertal Children With Growth Hormone Deficiency (GHD)
NCT02781727 is registered in ClinicalTrials.gov with Ascendis Pharma Endocrinology Division A/S as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Phase 3, Randomized, Open-label, Active-controlled, Parallel-group Trial Investigating the Safety, Tolerability, and Efficacy of TransCon hGH Administered Once a Week Versus Standard Daily hGH Replacement Therapy Over 52 Weeks in Prepubertal Children With Growth Hormone Deficiency (GHD)
- Lead sponsor
- Ascendis Pharma Endocrinology Division A/S
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- December 13, 2016
- Completion date
- January 17, 2019
- Enrollment
- 162 (actual)
- Sites
- 53
Conditions
As the registry lists them; a condition with its own page is linked.
endocrine system diseases, growth hormone deficiency, pediatric, hgh (human growth hormone), hormones, pituitary diseases